Abstracts offer insights into precision
oncology diagnostics for triple-negative breast cancer, liquid
biopsy and machine learning for tumor profiling
BURLINGTON, N.C., May 30, 2024
/PRNewswire/ -- Labcorp (NYSE: LH), a global leader of
innovative and comprehensive laboratory services, will present
several abstracts at the 2024 American Society of Clinical Oncology
(ASCO) Annual Meeting in Chicago
(May 31 – June
4, 2024).
Labcorp's oncology research highlights the company's dedication
to advancing meaningful and actionable insights that enhance the
understanding of tumor biology and immune system mechanisms. These
insights will contribute to facilitating patient access to novel
targeted therapies with the end goal of improving patient
outcomes.
"Labcorp is committed to deepening the understanding of cancer
biology and enhancing therapeutic strategies. Through our
presentations at the ASCO Annual Meeting investigating critical
aspects of triple-negative breast cancer, liquid biopsy, and
employing advanced machine learning algorithms for tumor profiling,
we are paving the way for more accurate diagnostics and effective
treatments," said Shakti Ramkissoon, M.D., Ph.D., MBA, vice
president, medical lead for oncology at Labcorp. "These studies
exemplify Labcorp's deep scientific and medical expertise enabling
delivery of compelling evidence through internal and external
collaborations to drive advancements in precision oncology."
Of the eight abstracts to be presented at the ASCO Meeting, four
were internal studies by Labcorp researchers and four were
conducted in collaboration with research partners from premier
academic institutions and medical centers.
Among those being presented by Labcorp researchers, the findings
of two studies examine various aspects of triple-negative breast
cancer (TNBC) to provide a deeper understanding of the factors
causing tumor progression and therapy resistance in the disease.
Triple-negative breast cancer accounts for approximately 10-15% of
all breast cancers but disproportionately impacts Black women in
the U.S., who have almost twice the rate of the disease compared to
white women.
Session: Breast Cancer-Metastatic
Abstract: 1096 - Interaction between VEGF-A and
immune checkpoint targets in triple-negative breast cancer suggests
a mechanism of immune evasion and tumor progression.
Poster Board: 74
Date: Sunday, June 2,
9:00 a.m. – 12:00 p.m. CDT
Vascular endothelial growth factor (VEGF) promotes angiogenesis and
potentially modulates tumor immune evasion in breast cancer.
Labcorp researchers performed comprehensive genomic and immune
profiling on 143 formalin-fixed paraffin-embedded breast cancer
samples to investigate the interaction between VEGF and
immune gene expression. In triple-negative breast cancer
(TNBC) samples, VEGF was co-expressed with immune checkpoint genes
such as PD-1 and PD-L1. Labcorp's findings support that
angiogenesis mediators may enhance immunosuppression, leading to
immune evasion and tumor progression in TNBC.
Session: Breast Cancer—Metastatic
Abstract: 1095 – Novel HLA-Ilo/HLA-IIhi phenotype
and immune evasion in triple-negative breast cancer.
Poster Board: 73
Date: Sunday, June 2,
9:00 a.m. – 12:00 p.m. CDT
Resistance and non-response to immunotherapy remain an unmet
clinical need for patients with triple-negative breast cancer
(TNBC). Aberrant expressions of human leukocyte antigens (HLAs) are
one mechanism by which cancer cells evade immune response. Labcorp
researchers performed a targeted RNA-sequence-based assay on 143
breast cancer patient samples, demonstrating that concurrent loss
of HLA class I with increased HLA class II expression was
associated with co-expression of biomarkers indicative of immune
escape but not survival outcomes. These data offer an opportunity
for developing novel approaches to overcome immunotherapy
resistance in TNBC.
Session: Care Delivery/Models of Care
Abstract: 1554 - A machine learning algorithm based on
multi-omics biomarkers for the detection of tumor microsatellite
instability
Poster Board: 425
Date: Saturday, June 1,
9:00 a.m. – 12:00 p.m. CDT
Labcorp researchers will present data on an innovative machine
learning model developed to predict microsatellite instability
(MSI) status in patients with solid tumors using comprehensive
genomic and immune profiling, independent of direct sequencing data
from microsatellite sites. Researchers analyzed genomic and gene
expression data from over 2,000 colorectal cancer samples to
generate and test a model for predicting MSI status, which was
confirmed using MSI status from The Cancer Genome Atlas (TCGA)
studies of colorectal and endometrial carcinoma. This study
highlights an algorithmic method to identify patients with
potential MSI-high status for orthogonal screening when current
methodologies fall short.
Session: Developmental Therapeutics-Molecularly Targeted
Agents and Biology
Abstract: 3063 - Analytical Validation of the
Labcorp® Plasma Complete™ Test to Enable Precision Oncology Through
Solid Tumor Liquid Biopsy Comprehensive Genomic Profiling
Poster Board: 208
Date: Saturday, June 1,
9:00 a.m. – 12:00 p.m. CDT
The Labcorp® Plasma Complete™ test is a next-generation-sequencing,
cell-free DNA comprehensive genomic profiling test that identifies
actionable and clinically relevant variants in advanced and
metastatic solid cancers across 521 genes. In this validation
study, test performance demonstrated highly specific (>99.99%),
accurate (97.3% positive percent agreement and >99.99% negative
percent agreement) and sensitive (down to 0.35% or 1.63-fold)
variant detection. Plasma samples from a broad range of solid
tumors demonstrated that this assay offers a highly precise,
accurate, and robust comprehensive genomic and immune profiling
assay to complement tissue-based testing and inform clinical
decision-making.
To connect with Labcorp at the 2024 ASCO Annual Meeting in
Chicago, visit
https://oncology.labcorp.com/ASCO24.
About Labcorp
Labcorp (NYSE: LH) is a global leader of
innovative and comprehensive laboratory services that helps
doctors, hospitals, pharmaceutical companies, researchers and
patients make clear and confident decisions. We provide insights
and advance science to improve health and improve lives through our
unparalleled diagnostics and drug development laboratory
capabilities. The company's more than 67,000 employees serve
clients in approximately 100 countries, provided support for 84% of
the new drugs and therapeutic products approved in 2023 by the FDA,
and performed more than 600 million tests for patients around the
world. Learn more about us at www.labcorp.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/labcorp-to-present-multiple-abstracts-across-precision-oncology-at-the-2024-asco-annual-meeting-302159256.html
SOURCE Labcorp